Cancer drugmaker stocks present an interesting opportunity to investors. Although there is no guarantee a company with a drug in the pipeline will be approved, let alone become popular (two reasons why the biotech industry is wrought with risk), getting in early can mean big returns if the company releases a blockbuster drug.
These stocks can quickly rise in value if they pass certain goals in testing, reach approval, or reach commercial success. They can also rise in value when the companies present their research at the American Society of Clinical Oncology (ASCO), which holds their annual meeting in June. These presentations can be real game changers for the world of medicine, and for stock values.
Business section: Investing ideas
The society will be posting research abstracts for the meeting on its website May 16th. Until then, there are seven companies with stocks expected to present at this year's ASCO meeting.
TheStreet.com has compiled some need-to-know information on these companies for investors. Do you agree it would be wise to keep these names on your radar? (Click here to access free, interactive tools to analyze these ideas.)
1. Celldex Therapeutics
3. Johnson & Johnson
4. Ariad Pharmaceuticals
5. Aveo Pharmaceuticals
Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned above. Analyst ratings sourced from Zacks Investment Research.
Kapitall's Rebecca Lipman does not own any of the shares mentioned above.
The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy.